Insider Trading March 23, 2026

Thryv Director John Slater Buys $5,320 of Stock as Company Faces Mixed Results

Slater increases stake amid a sharp share-price decline and recent earnings miss that prompted analyst target cuts

By Sofia Navarro THRY
Thryv Director John Slater Buys $5,320 of Stock as Company Faces Mixed Results
THRY

Thryv Holdings director John Slater purchased 2,000 shares of the company's common stock on March 17, 2026, at $2.66 per share, a transaction valued at $5,320. The buy comes while the stock trades at $2.97, down 81% over the past year and trading close to a 52-week low of $1.91. Recent fourth-quarter 2025 results missed EPS expectations but edged revenue above forecasts, prompting analysts to lower price targets as the company shifts strategy toward higher-value customers.

Key Points

  • Director John Slater purchased 2,000 shares on March 17, 2026 at $2.66 per share, totaling $5,320, increasing his holdings to 40,370 shares.
  • Thryv's stock trades at $2.97, down 81% over the past year and close to a 52-week low of $1.91; InvestingPro analysis flags THRY as trading below its Fair Value.
  • Q4 2025 results showed an EPS miss of -$0.22 versus a $0.18 forecast and revenue of $191.62 million slightly above the $191.25 million estimate; analysts reduced price targets and adjusted ratings.

Director John Slater of Thryv Holdings, Inc. (NASDAQ: THRY) completed a purchase of 2,000 shares of the company's common stock on March 17, 2026. The shares were acquired at $2.66 apiece, giving the transaction a total value of $5,320.

Following this purchase, Slater's direct ownership in Thryv totals 40,370 shares. At the time the purchase was noted, Thryv's shares were trading at $2.97, a level that reflects an 81% decline over the prior 12 months and sits near the 52-week low of $1.91.

Market-value commentary included with the transaction notes that InvestingPro analysis classifies THRY as trading below its Fair Value, listing the company among the platform's most undervalued names. Investors seeking deeper company analysis are directed to a Pro Research Report on THRY, one of more than 1,400 U.S. equities covered on that platform.


The insider purchase occurs in the context of Thryv's recently reported fourth-quarter 2025 financials. The company reported adjusted earnings per share of -$0.22, missing the consensus forecast of $0.18 and creating an earnings surprise of -222.22%. Revenue for the quarter was $191.62 million, which modestly exceeded the consensus estimate of $191.25 million.

In response to the quarter's results, analysts have revised their outlooks. Craig-Hallum lowered its price target for Thryv to $4.00 from $10.00 while maintaining a Hold rating, citing the company's strategic pivot toward higher-value customers. Needham also cut its price target, reducing it from $14 to $6, while retaining a Buy rating and noting that the firm's financial results were broadly in line with expectations despite weak customer growth.

These developments - the director purchase, the significant year-on-year share-price decline, the Q4 earnings miss contrasted with slightly better-than-expected revenue, and subsequent analyst adjustments - present a mix of signals that market participants will weigh as they assess Thryv's near-term trajectory.

Investors and analysts monitoring the situation can reference proprietary valuation tools, such as the Fair Value calculator cited by market commentary, which aggregates multiple valuation models to gauge whether THRY is trading beneath intrinsic value levels.

Risks

  • Earnings volatility: The significant EPS miss in Q4 2025 highlights potential near-term earnings risk for shareholders, impacting small-cap and software/services investors.
  • Customer-growth weakness: Analyst commentary points to weak customer growth, which could pressure revenue expansion and market positioning in Thryv's served markets.
  • Price and sentiment risk: A steep 81% year-over-year share-price decline and proximity to a 52-week low indicate elevated market risk and potential volatility for equity holders.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026